For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
2
views
52
references
 Top references
cited by
9
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      129
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Recurrence of disease due to chemotherapy drug resistance remains a major obstacle to a more successful survival outcome of multiple myeloma (MM). Overcoming drug resistance and salvaging patients with relapsed and/or refractory (R/R) MM is an urgent and unmet medical need. Several new personalized treatment strategies have been developed against molecular targets to overcome this drug resistance. There are several targeted therapeutics with anti-MM activity in clinical pipeline, including inhibitors of anti-apoptotic proteins, monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, and various cell therapy platforms. For example, B-cell maturation antigen (BCMA)-specific CAR-T cell platforms showed promising activity in heavily pretreated R/R MM patients. Therefore, there is renewed hope for high-risk as well as R/R MM patients in the era of personalized medicine.

          Highlights

          • •

            The therapeutic landscape for MM is rapidly evolving in the era of personalized medicine

          • •

            New treatment strategies have markedly improved the survival of MM patients and caused a paradigm shift in therapy

          Related collections

          Most cited references52

          • Record: found
          • Abstract: found
          • Article: not found

          Genomic complexity of multiple myeloma and its clinical implications

          Salomon Manier, Karma Salem, Jihye Park … (2016)
          In the past 5 years, results from large-scale whole-exome sequencing studies have brought new insight into the clonal heterogeneity and evolution of multiple myeloma, a genetically complex disease. Herein, the authors describe the driver gene alterations and sequential acquisition of the main genomic aberrations involved in this disease, with a focus on the clonal heterogeneity of multiple myeloma and its clinical implications.
          Article 0 comments Cited 214 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Curing myeloma at last: defining criteria and providing the evidence.

            Bart Barlogie, Alan Mitchell, Frits Rhee … (2014)
            Does the dogma that multiple myeloma is incurable still hold?. The genomic chaos and resulting resistance to apoptosis of myeloma, long considered an obstacle to cure, formed the basis of Total Therapy (TT) program. The TT approach uses all myeloma-active drugs upfront to target drug-resistant subclones during initial treatment to prevent later relapse. Long-term follow-up of 1202 patients (TT1: n = 231, median follow-up: 21 years; TT2: 668, median follow-up: 12 years; TT3a: n = 303, median follow-up: 9 years) permitted investigation of whether progression-free survival (PFS) and complete response (CR) duration were consistent with curability, ie observation of plateaus in Kaplan-Meier plots for PFS and CR duration. In the subset of 627 patients with plasma cell gene expression profiling data, cure plateaus were apparent at 5 years in the 14% with high-risk myeloma compared with 10 years in the remainder with low-risk disease. A parametric model based on PFS and CR duration supported an increase in curability: 10-year PFS and CR estimates increased from 8.8%/17.9% in TT1 to 15.5%/28.2% in TT2's control arm to 25.1%/35.6% in TT2's thalidomide arm and to 32.9%/48.8% in TT3a. Toward developing novel therapies, we recommend a concerted focus on patients with high-risk myeloma whose outcome has not been advanced.
            Article 0 comments Cited 96 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found
              Is Open Access

              Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

              Meletios A. Dimopoulos, Sagar Lonial, Keith Betts … (2018)
              Article 0 comments Cited 61 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Contributors
                Fatih M. Uckun
                Journal
                Journal ID (nlm-ta): EBioMedicine
                Journal ID (iso-abbrev): EBioMedicine
                Title: EBioMedicine
                Publisher: Elsevier
                ISSN (Electronic): 2352-3964
                Publication date PMC-release: 10 December 2018
                Publication date Collection: January 2019
                Publication date (Electronic): 10 December 2018
                Volume: 39
                Pages: 612-620
                Affiliations
                [a ]Immuno-Oncology Program, Ares Pharmaceuticals, St. Paul, MN 55110, USA
                [b ]Norris Comprehensive Cancer Center and Childrens Center for Cancer and Blood Diseases, University of Southern California Keck School of Medicine (USC KSOM), Los Angeles, CA 90027, USA
                [c ]Bioinformatics Program, Gustavus Adolphus College, 800 W College Avenue, St. Peter, MN 56082, USA
                [d ]Ankara University School of Medicine, Cebeci Hospital, Cebeci, 6590 Cankaya, Ankara, Turkey
                [e ]Department of Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
                Author notes
                [* ]Corresponding author at: Ares Pharmaceuticals, St. Paul, MN 55110, USA. fatih.uckun@ 123456aresmit.com
                Article
                Publisher ID: S2352-3964(18)30575-9
                DOI: 10.1016/j.ebiom.2018.12.004
                PMC ID: 6354702
                PubMed ID: 30545798
                SO-VID: 8741d87b-2f2c-45b0-a734-0c786e412d17
                Copyright © © 2018 The Authors
                License:

                This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                Date received : 25 October 2018
                Date revision received : 4 December 2018
                Date accepted : 4 December 2018
                Categories
                Subject: Review

                Keywords: personalized medicine,multiple myeloma,stem cell transplantation,immuno-oncology,immunotherapy,biotherapy
                Data availability:
                Keywords: personalized medicine, multiple myeloma, stem cell transplantation, immuno-oncology, immunotherapy, biotherapy

                Comments

                Comment on this article

                scite_

                Similar content129

                See all similar

                Cited by12

                See all cited by

                Most referenced authors1,431

                See all reference authors